Drug notes:
Also Clin1 multiple cancers; BCA356 Clin0 solid tumors; undisclosed programs RD solid tumors
About:
Bicara Therapeutics is developing bifunctional antibodies for precision targeted therapies in immuno-oncology. Cancers use various mechanisms to prevent the immune system from their clearance including manipulating the tumor microenvironment. Bicara is using their platform to design bifunctional molecules that precisely target the tumor and deliver a tumor-modulating payload. Besides tumor cell recognition, the second function of the drug is to trap signaling molecules in the tumor microenvironment. By delivering a payload to the tumor, Bicara’s strategy minimizes side effects as lower doses of drug are required for the anti-tumor effect. Bicara’s lead program, BCA101, is in clinical trials for patients with squamous cell carcinoma.